Desano Pharmaceuticals of Shanghai struck a deal with ViiV Healthcare to produce the active ingredient of GlaxoSmithKline’s new HIV drug, dolutegravir, an integrase strand transfer inhibitor. ViiV was formed in 2009 by GSK and Pfizer to offer cost-effective HIV treatments to less-developed countries. Shionogi joined in 2012. By outsourcing the production of the API to Desano, ViiV can lower the cost. ViiV intends to combine dolutegravir with anti-retrovirals to make the combination therapy Tivicay.
Help employers find you! Check out all the jobs and post your resume.
